Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN HF 8 versus TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN HF 8 versus TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 5 IN PLASTIC CONTAINER.
AMINOSYN-HF 8% vs TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn-HF 8% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, promoting nitrogen balance and tissue repair in patients unable to tolerate oral intake.
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% is a crystalline amino acid solution combined with electrolytes and dextrose. Amino acids provide substrates for protein synthesis, dextrose supplies calories to minimize protein catabolism, and electrolytes maintain acid-base and electrolyte balance.
1-2 g/kg/day intravenously as total parenteral nutrition, typically administered as a continuous infusion over 24 hours.
Intravenous infusion: 500-1000 mL administered over 1-2 hours per day, adjusted based on electrolyte and fluid requirements. Typical adult dose provides 2.75% amino acids and 5% dextrose with electrolytes.
None Documented
None Documented
Not applicable as amino acids are rapidly cleared; terminal half-life of infused amino acids is approximately 10-30 minutes.
Amino acids: 15-30 min (rapid redistribution). Dextrose: 1-2 h. Clinical context: continuous infusion maintains steady state.
Renal: >90% as amino acids and metabolites; fecal: <5%.
Renal: >95% of infused amino acids and dextrose metabolites excreted as urea, CO2, and water. Biliary/fecal: negligible.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution